Latest News on CRL

Financial News Based On Company


Advertisement
Advertisement

Should You Continue to Hold Charles River Stock in Your Portfolio?

https://www.tradingview.com/news/zacks:fac182df8094b:0-should-you-continue-to-hold-charles-river-stock-in-your-portfolio/
Charles River Laboratories International (CRL) is experiencing improving demand, bookings, and backlog in its Discovery and Safety Assessment (DSA) segment, along with a strong solvency position, which supports its growth. However, the company faces competitive pressures and unfavorable foreign exchange rates that could impact its performance. The article recommends a "Hold" rating for CRL stock due to these mixed factors.

Europe approves the first once-daily pill for eligible adults with a chronic, painful skin disease.

https://www.stocktitan.net/news/INCY/povofortay-povorcitinib-approved-in-europe-as-the-first-once-daily-wtpdd3wpecar.html
The European Commission has approved Incyte's Povofortay (povorcitinib) as the first once-daily oral treatment for eligible adults with moderate to severe hidradenitis suppurativa (HS). This approval is based on Phase 3 STOP-HS1 and STOP-HS2 trials, which demonstrated the drug's efficacy and tolerability over 54 weeks. The U.S. Food and Drug Administration is also reviewing povorcitinib, with a potential approval and launch in the first quarter of 2027.

T. Rowe Price reports a Charles River (CRL) stake with sole voting power over 2.77M shares.

https://www.stocktitan.net/sec-filings/CRL/schedule-13g-charles-river-laboratories-international-inc-passive-inv-2f30a6250236.html
T. Rowe Price Associates, Inc. has filed a Schedule 13G, disclosing a 6.3% beneficial ownership stake in Charles River Laboratories International, Inc. (CRL) as of September 30, 2026. The firm reported sole voting power over 2,768,367 shares and sole dispositive power over 3,010,619 shares, while explicitly denying beneficial ownership. This filing indicates a significant passive investment in Charles River.

VivoSim Labs to present liver and intestine toxicity data at ACT meeting

https://www.streetinsider.com/Corporate+News/VivoSim+Labs+to+present+liver+and+intestine+toxicity+data+at+ACT+meeting/27348959.html
VivoSim Labs, Inc. (Nasdaq: VIVS) announced it will present two studies at the 2026 American College of Toxicology Annual Meeting, focusing on liver and gastrointestinal toxicity. The presentations will showcase data from their NAMkind™ Liver and NAMkind™ Intestine platforms, which utilize 3D human cellular models to assess drug toxicity. These platforms aim to identify drug-induced organ injury more effectively than traditional animal models, particularly for compounds that failed in human clinical trials due to liver or GI toxicity.

VivoSim Labs Presents Landmark NAMkind™ Liver and Intestine Toxicology Studies at ACT Annual Meeting

https://www.quiverquant.com/news/VivoSim+Labs+Presents+Landmark+NAMkind%E2%84%A2+Liver+and+Intestine+Toxicology+Studies+at+ACT+Annual+Meeting
VivoSim Labs announced it is presenting two significant studies at the 2026 American College of Toxicology Annual Meeting, showcasing its NAMkind™ Liver and Intestine platforms. These platforms use 3D human models to identify drug-induced liver injury and gastrointestinal toxicity more effectively than traditional animal tests, which often miss human-specific liabilities. The studies demonstrated the models' ability to flag toxicity in drug candidates that previously passed animal tests but failed in human trials, offering a valuable tool for biopharma developers to reduce costly clinical failures and optimize lead candidate selection.
Advertisement

One quarter brought PMGC more revenue than all of 2025 combined.

https://www.stocktitan.net/news/ELAB/pmgc-holdings-inc-nasdaq-elab-reports-record-q3-revenue-up-785-year-s8hfcvjq7zq9.html
PMGC Holdings Inc. [NASDAQ: ELAB] reported record Q3 2026 revenue of approximately $2.53 million, marking a 785% year-over-year increase and 94% sequential growth, primarily due to full quarterly contributions from its five acquisitions. The company also announced the consolidation of its sponsored SPAC, NorthStrive Acquisition Corp I (NSAI), including $100.4 million in a restricted trust, and detailed NSAI's definitive agreement for a proposed business combination with Nuclea Energy Inc. PMGC continues to expand its operating base and advance defense technology and biosciences development programs.

Charles River Labs to close Mass. site, transfer operations

https://www.bizjournals.com/boston/news/2026/11/14/charles-river-labs-to-close-worcester-ma-site.html
Charles River Laboratories is closing its Worcester, Massachusetts site and transferring its drug metabolism and pharmacokinetics operations to a new Shrewsbury facility. This consolidation is projected to generate over $300 million in cumulative savings for the company through 2030. The company is headquartered in Wilmington, Massachusetts.

Charles River Strengthens Global Microbial Solutions Network Through Investments in Manufacturing, Customer Support, and Sustainability

https://www.biospace.com/press-releases/charles-river-strengthens-global-microbial-solutions-network-through-investments-in-manufacturing-customer-support-and-sustainability
Charles River Laboratories International, Inc. announced strategic investments to strengthen its global Microbial Solutions network. These enhancements include expanding manufacturing capacity for endotoxin testing products in Dublin, Ireland, launching an Instrument Service Depot in South Korea to improve customer support in Asia-Pacific, and advancing sustainable laboratory operations, with its Charleston, South Carolina Celsis Application Laboratory achieving Gold-Level My Green Lab Certification. These efforts aim to accelerate quality control workflows and ensure product quality and patient safety worldwide.

With no revenue from continuing operations, Advanced Biomed (ADVB) posts a wider loss.

https://www.stocktitan.net/sec-filings/ADVB/10-q-advanced-biomed-inc-quarterly-earnings-report-af239a8bac44.html
Advanced Biomed Inc. (ADVB) reported no revenue from continuing operations for the quarter ended September 30, 2026, and its net loss widened to $989,054 from $147,155 in the prior year. The increased loss was primarily due to higher general and administrative expenses, including a significant provision for expected credit losses. The company has shifted its focus from biotechnology to AI and financial algorithmic software activities, with its liquidity partially dependent on collecting receivables from former subsidiaries.

Greater Philadelphia Life Sciences News: INOVIO's $75M Offering, Waters' MOBILion Acquisition & More

https://biobuzz.io/news/greater-philadelphia-life-sciences-news-inovio-s-75m-offering-waters-mobilion-acquisition/
The Greater Philadelphia life sciences ecosystem is experiencing significant activity, with companies raising capital, acquiring capabilities, and building talent pipelines. Notable events include INOVIO Pharmaceuticals pricing a $75 million public offering, Waters Corporation acquiring MOBILion Systems, and Charles River Laboratories expanding its preclinical drug development platform through an acquisition from Frontage. Additionally, the region is seeing leadership appointments and new healthcare training initiatives.
Advertisement

Charles River Strengthens Global Microbial Solutions Network Through Investments in Manufacturing, Customer Support, and Sustainability

https://www.stocktitan.net/news/CRL/charles-river-strengthens-global-microbial-solutions-network-through-k2gqwqhgznob.html
Charles River Laboratories International, Inc. (NYSE: CRL) has announced strategic investments to enhance its global Microbial Solutions network. These enhancements include expanding manufacturing capacity in Dublin, Ireland for endotoxin testing products, launching a new Instrument Service Depot in South Korea to improve customer support in Asia-Pacific, and advancing sustainable laboratory operations, with the Charleston, South Carolina Celsis Application Laboratory achieving Gold-Level Certification from My Green Lab. These efforts aim to improve efficiency, responsiveness, and sustainability for customers in pharmaceutical, biotechnology, cell and gene therapy, and medical device manufacturing.

Clients hold the 1.85M Charles River (CRL) shares underlying Invesco’s reported 3.9% stake.

https://www.stocktitan.net/sec-filings/CRL/schedule-13g-a-charles-river-laboratories-international-inc-amended-p-41f02c7e3a79.html
Invesco Ltd. has reported a beneficial ownership of 1,852,539 shares of Charles River Laboratories International, Inc. (CRL), representing 3.9% of the common stock. These shares are held by Invesco clients, who retain the economic rights, including dividends and sale proceeds. Invesco itself maintains sole voting power over 1,845,388 shares and sole dispositive power over all 1,852,539 shares.

Charles River Laboratories Recent $470 Million Deal an 'Attractive Strategic Addition,' Analyst Says

https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/11/63093452/charles-river-laboratories-recent-470-million-deal-an-attractive-strategic-addition-analyst-says
Charles River Laboratories International Inc. is set to acquire Frontage Holdings Corporation's bioanalysis and DMPK operations for $470 million cash, with an additional $75 million in earnouts. This acquisition aims to expand Charles River's clinical bioanalysis capabilities, balancing its lab testing portfolio and capitalizing on the growing global bioanalysis market. An analyst from William Blair views the deal as a strategic addition that aligns with Charles River's growth priorities in bioanalysis.

Hangzhou Tigermed Consulting Co., Ltd. Proposes Frontage Privatization and Overseas Asset Sale

https://www.tradingview.com/news/tradingview:0ee52cde985dd:0-hangzhou-tigermed-consulting-co-ltd-proposes-frontage-privatization-and-overseas-asset-sale/
Hangzhou Tigermed Consulting Co., Ltd. has proposed to privatize its controlled subsidiary, Frontage Holdings Corporation, and subsequently divest Frontage's overseas laboratory services business to Charles River Laboratories International, Inc., Dr. Song Li, and his trusts. This move is expected to refocus Tigermed on clinical CRO services and its China business, with anticipated proceeds and investment gains, though no specific amounts were disclosed. The proposals are subject to various conditions and implementation requirements.

Overseas lab services may be sold as Tigermed keeps Frontage's China business

https://www.stocktitan.net/news/CRL/tigermed-to-participate-in-the-privatization-of-frontage-holdings-tdd41jxswgtu.html
Tigermed proposes to privatize its controlled subsidiary Frontage Holdings Corporation and subsequently divest Frontage's overseas laboratory services business to Charles River Laboratories International and Frontage Chairman Dr. Song Li. Tigermed will retain Frontage's China business, a move designed to optimize strategic planning, capital allocation, and operational efficiency while strengthening its core clinical contract research organization (CRO) business in China. This restructuring is expected to generate proceeds and investment gains for Tigermed shareholders.
Advertisement

In Vitro Toxicology Testing - Global Strategic Business Report: Capitalize on the $14B-to-$27.4B Surge as Thermo Fisher Scientific, Merck, Eurofins and Bio-Rad Disrupt Testing by 2032

https://sg.finance.yahoo.com/news/vitro-toxicology-testing-global-strategic-145800531.html
The global in vitro toxicology testing market, valued at US$14 billion in 2025, is projected to reach US$27.4 billion by 2032, driven by regulatory shifts away from animal testing and advancements in human-relevant models, AI, and high-throughput screening. This growth is significantly influenced by pharmaceutical, biotechnology, cosmetics, and food safety industries adopting these technologies to accelerate safety assessments and reduce development costs. Key players like Thermo Fisher Scientific, Merck, Eurofins, and Bio-Rad are at the forefront of this market disruption.

Charles River Laboratories to Acquire Frontage Bioanalysis Businesses for Up to $545 Million

https://www.citybiz.co/article/930990/charles-river-laboratories-to-acquire-frontage-bioanalysis-businesses-for-up-to-545-million/
Charles River Laboratories International (NYSE: CRL) has agreed to acquire the bioanalysis and DMPK businesses of Frontage Holdings Corporation for up to $545 million. This acquisition, which includes two laboratory facilities in Exton, Pennsylvania, will expand Charles River's laboratory testing capabilities, particularly in clinical-stage development programs for biologics and complex therapies. The transaction aims to create a more balanced portfolio of preclinical and clinical testing services for Charles River and is expected to be neutral to non-GAAP earnings per share in 2027 and accretive thereafter.

Form 8K Charles River Laboratories International, Inc For: 9 November By Investing.com

https://in.investing.com/news/stock-market-news/form-8k-charles-river-laboratories-international-inc-for-9-november-93CH-5690020
This article announces that Charles River Laboratories International, Inc. has filed a Form 8K on November 9, 2026. The filing is an official document providing details on significant events that shareholders should know. The article, published by Investing.com, indicates the company's stock symbol is CRL, which was up 7.83% at the time of publication.

Is Charles River Laboratories International (CRL) Fully Valued After Raised EPS Guidance?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/is-charles-river-laboratories-international-crl-fully-valued
Charles River Laboratories International (CRL) has seen a significant share price jump following strong Q3 earnings and raised full-year 2026 GAAP EPS guidance, largely due to a one-time tax reserve reversal. While Simply Wall St's analyst consensus suggests the stock is 2% overvalued with a fair value of $332.20, a Discounted Cash Flow (DCF) model indicates it might be even more overvalued at $298.11 per share. Investors are encouraged to weigh these contrasting views and consider potential risks like a shift to non-animal testing or softening biopharma funding.

Charles River Laboratories to Acquire Frontage’s Bioanalysis and DMPK Businesses

https://sg.finance.yahoo.com/news/charles-river-laboratories-acquire-frontage-111000148.html
Charles River Laboratories International, Inc. announced its definitive agreement to acquire Frontage Holdings Corporation's bioanalysis and DMPK operations in Exton, Pennsylvania, for approximately $470 million in cash, with potential additional payments of up to $75 million. This acquisition aims to expand Charles River's bioanalysis capabilities, particularly in clinical bioanalysis, and enhance its support for clients across the drug development lifecycle, especially for biologics and complex modalities. The transaction, expected to close in the first half of 2027, will strengthen Charles River's presence in a high-growth market and is projected to be neutral to non-GAAP earnings per share in 2027 and accretive thereafter.
Advertisement

Charles River Stock In Focus After Higher EPS Guidance And Tax Reserve Reversal

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/charles-river-stock-in-focus-after-higher-eps-guidance-and-t
Charles River Laboratories International (NYSE: CRL) has increased its 2026 GAAP EPS guidance to US$8.15 to US$8.35, primarily due to a third-quarter tax reserve reversal, despite mild top-line pressure. The company's investment narrative continues to focus on operational efficiency and the development of New Approach Methodologies like Virtual Control Groups to mitigate risks from softening demand in traditional research models. Analysts forecast the company to reach US$4.5 billion in revenue and US$578.0 million in earnings by 2029.

Health Care sector performance - S&P 500 health care stocks

https://www.quantisnow.com/sector-performance/health-care
The S&P 500 Health Care sector, comprising 59 companies worth $6.93 trillion, experienced a -0.15% decline on the day of November 6, 2026, despite a +19.5% year-to-date performance. Moderna Inc., Humana Inc., and Charles River Laboratories International Inc. were among the top gainers, while Insulet Corporation and DexCom Inc. were among the top losers. The article provides detailed performance metrics for each company within the sector, including daily, weekly, monthly, quarterly, year-to-date, and annual changes.

Will Raised Revenue Guidance Change Haemonetics Stock Narrative

https://simplywall.st/stocks/us/healthcare/nyse-hae/haemonetics/news/will-raised-revenue-guidance-change-haemonetics-stock-narrat
Haemonetics reported strong Q2 fiscal 2027 results, with sales of US$357.76 million and net income of US$46.31 million, leading to an increase in its full-year revenue growth guidance to 8-11%. This positive outlook is driven by organic revenue growth across its key segments and new regulatory clearances, reinforcing a narrative of recurring, procedure-linked revenue streams. The company's ability to maintain this growth amidst cost pressures and a significant debt load will be crucial for its sustained profitability and investor confidence.

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day

https://www.marketwatch.com/data-news/charles-river-laboratories-international-inc-stock-outperforms-competitors-on-strong-trading-day-27d5b706-89815225b726
Charles River Laboratories International Inc. (CRL) stock saw a significant increase of 7.83% to $337.52, outperforming the S&P 500 which rose 0.31% and the Dow Jones Industrial Average which fell 0.46%. This rise broke a two-day losing streak for the company's shares.

Danaher (DHR) Won FDA Clearances, Is The Discount Too Cautious?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/danaher-dhr-won-fda-clearances-is-the-discount-too-cautious
Danaher (DHR) has gained renewed investor interest following recent FDA clearances for its Cepheid Xpert Hemorrhagic Fever Panel and Beckman Coulter Access MeMed BV assay, enhancing its infectious disease and antimicrobial testing portfolio. Despite positive share price momentum and higher long-term revenue guidance, the stock trades at a discount to analyst targets and intrinsic value estimates. The article explores whether the market is appropriately cautious about execution risks or overly skeptical of Danaher's new diagnostics pipeline and growth prospects.
Advertisement

ICON (ICLR) Launches FIRECREST AI Video Engine For Clinical Trial Communications

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iclr/icon/news/icon-iclr-launches-firecrest-ai-video-engine-for-clinical-tr
ICON plc (NasdaqGS:ICLR) has launched its FIRECREST AI-Directed Video Engine, an AI-powered tool designed to automate and standardize clinical trial communications for sites and patients. This new platform aims to enhance productivity and streamline workflows within ICON's existing FIRECREST clinical technology suite, reinforcing the company's focus on leveraging digital tools to improve operational efficiency. The move is expected to contribute to operating leverage and the commercial appeal of ICON's platform, rather than immediate revenue growth, with investors encouraged to monitor its adoption and impact on business wins.

Charles River Laboratories International, Inc. Just Beat EPS By 244%: Here's What Analysts Think Will Happen Next

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/charles-river-laboratories-international-inc-just-beat-eps-b
Charles River Laboratories International (NYSE: CRL) significantly surpassed analyst expectations for its quarterly results, with revenues beating forecasts by 2.3% and statutory profit exceeding estimates by an impressive 244%. Despite the strong quarterly performance, analysts have not made major changes to their 2027 revenue and EPS forecasts, reconfirming a price target of US$319. However, the company's projected revenue growth of 0.8% annually until 2027 is expected to be slower than its historical five-year growth and the broader industry.

Charles River Laboratories International Q3 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:dbda72bfb094b:0-charles-river-laboratories-international-q3-earnings-call-highlights/
Charles River Laboratories International (CRL) exceeded its Q3 forecasts, with organic revenue up 4.7% and non-GAAP earnings per share rising 27.2% to $3.09, driven by strong demand in safety assessment and manufacturing testing. The company raised its full-year 2026 organic revenue and non-GAAP earnings per share outlook, despite a decline in research models and services. Strategic initiatives, including a transformation program and expansions in bioanalysis, are expected to support future growth, with a target of 5% to 7% organic growth by 2028.

Charles River Raises 2026 Non-GAAP EPS Outlook to $11.35-$11.55

https://www.tokenpost.com/news/business/49461
Charles River Laboratories International, Inc. has raised its 2026 non-GAAP earnings-per-share outlook to $11.35-$11.55, following stronger-than-expected third-quarter results. The company also lifted its organic revenue-growth forecast to at least 1.5% and anticipates approximately 150 basis points of sequential margin improvement in the fourth quarter. These updates reflect continued momentum in the improving biopharmaceutical demand environment.

Charles River Laboratories International (CRL) Stock May Be Fully Priced Following Its 95% Run

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/charles-river-laboratories-international-crl-stock-may-be-fu
Charles River Laboratories International (CRL) stock has seen a significant 94.6% return over the past year, leading to questions about whether its current share price is justified by its intrinsic value and future cash flows. A Discounted Cash Flow (DCF) model suggests the stock's current price of $326.29 is broadly in line with its estimated intrinsic value, reflecting market expectations from recently raised guidance and a new "Pathway to Purpose" plan. While community narratives offer both bull and bear cases, the consensus leans towards the stock being roughly fairly valued, with some potential for mix-driven operating margin expansion.
Advertisement

Charles River Laboratories International Inc (CRL) (Q3 2026) Earnings Call Highlights: ...

https://sg.finance.yahoo.com/news/charles-river-laboratories-international-inc-090601656.html
Charles River Laboratories International Inc (CRL) reported strong Q3 2026 results with organic revenue growth of 4.7%, the highest in three years, and non-GAAP EPS up 27.2% year over year. The company raised its full-year 2026 guidance, reflecting confidence in continued demand and operational execution, despite facing challenges in the RMS segment and persistent pricing pressure in DSA services. Key highlights included robust performance in DSA and Manufacturing segments, with strategic investments and modernization initiatives underway to support future growth and efficiency.

NorthStrive Biosciences Announces Results from EL-32

https://www.globenewswire.com/news-release/2026/11/05/3396318/0/en/northstrive-biosciences-announces-results-from-el-32-preclinical-combination-study-with-semaglutide-and-plans-for-next-phase-of-development.html
NorthStrive Biosciences, a subsidiary of PMGC Holdings Inc., announced preliminary results from a preclinical study of EL-32, an engineered probiotic designed to preserve muscle mass in patients undergoing GLP-1 weight loss treatments. The study, which evaluated EL-32 alone and in combination with semaglutide, found a statistically significant greater absolute lean mass at the highest EL-32 dose when combined with semaglutide. While the combination did not consistently demonstrate additive metabolic benefits over semaglutide alone, these findings will inform the design of a follow-on preclinical study.

Schrodinger Inc (SDGR) (Q3 2026) Earnings Call Highlights: Raised Guidance and Strong ACV ...

https://sg.finance.yahoo.com/news/schrodinger-inc-sdgr-q3-2026-051749755.html
Schrodinger Inc. (SDGR) reported strong Q3 2026 earnings, with ACV up 17% year-over-year and total revenue increasing by 19% to $64.5 million. The company raised its full-year 2026 ACV guidance to $222-$232 million and drug discovery revenue guidance to $75-$85 million, driven by a milestone payment from Structure's oral amylin program. Despite a widened net loss of $38 million, the company demonstrated disciplined expense management and a strong cash position of $373 million.

Charles River Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62870254/charles-river-q3-2026-earnings-call-transcript
Charles River Laboratories International, Inc. reported solid Q3 2026 financial performance, with revenue and non-GAAP EPS exceeding prior guidance, driven by strong growth in the DSA and manufacturing segments. The company raised its full-year 2026 guidance, expecting continued mid-single-digit growth and significant operating margin expansion. Management expressed optimism about improving biopharmaceutical demand and the long-term tailwind of AI in drug development.

Charles River Laboratories Announces Third-Quarter 2026 Results

https://www.biospace.com/press-releases/charles-river-laboratories-announces-third-quarter-2026-results
Charles River Laboratories reported strong third-quarter 2026 results, with revenue of $982.7 million and non-GAAP earnings per share of $3.09, exceeding prior expectations. The company also increased its 2026 guidance for revenue and non-GAAP earnings per share, driven by outperformance in its DSA segment and a lower tax rate. These results reflect continued strength in the biopharmaceutical demand environment and significant progress in strategic initiatives like Pathway to Purpose and Create the Future™.
Advertisement

Charles River Q3 Earnings & Revenues Top Estimates, Stock Rises

https://au.finance.yahoo.com/news/charles-river-q3-earnings-revenues-140100376.html
Charles River Laboratories (CRL) reported strong third-quarter 2026 results, with adjusted EPS of $3.09 and revenues of $982.7 million, both exceeding Zacks Consensus Estimates. The company's stock rose 2.9% pre-market following the announcement, driven by organic revenue growth, expanded margins, and an upward revision of its full-year 2026 guidance for both revenues and adjusted EPS. Despite a slight decline in reported revenues and the Research Models and Services segment, the Discovery and Safety Assessment and Manufacturing Solutions segments showed robust performance.

Form 8K Charles River Laboratories International, Inc For: 4 November By Investing.com

https://in.investing.com/news/stock-market-news/form-8k-charles-river-laboratories-international-inc-for-4-november-93CH-5678462
The article reports on a Form 8K filing by Charles River Laboratories International, Inc. on November 4th. It appears to be a basic news brief from Investing.com, providing essential information about the filing and including the company's stock performance. The article also provides various market data and other news snippets, typical of a financial news platform.

Form 8K Charles River Laboratories International, Inc For: 4 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-charles-river-laboratories-international-inc-for-4-november-93CH-4929290
This article announces that Charles River Laboratories International, Inc. has filed a Form 8K on November 4th. The filing is available through Investing.com, a financial markets platform. The article includes the stock symbol CRL and its current performance.

Charles River: Q3 Earnings Snapshot

https://sg.finance.yahoo.com/news/charles-river-q3-earnings-snapshot-122221243.html
Charles River Laboratories International Inc. (CRL) reported strong third-quarter results, with net income of $333.1 million and adjusted earnings of $3.09 per share, surpassing analyst expectations of $2.98 per share. The medical research equipment and services provider also exceeded revenue forecasts, posting $982.7 million against an expected $956.8 million. The company projects full-year earnings between $11.35 and $11.55 per share.

Non-GAAP EPS rises 27.2% as Charles River (CRL) raises its 2026 outlook.

https://www.stocktitan.net/sec-filings/CRL/8-k-charles-river-laboratories-international-inc-reports-material-eve-a39b80f94ea3.html
Charles River Laboratories International, Inc. (CRL) reported strong third-quarter 2026 results, with non-GAAP diluted EPS increasing 27.2% to $3.09, and organic revenue growing 4.7%. The company raised its 2026 organic revenue guidance to at least +1.5% and its non-GAAP EPS guidance to $11.35–$11.55, driven by outperformance in the DSA segment and a lower tax rate. GAAP net income also saw a significant boost due to a $245.6 million benefit from reversing acquired tax reserves.
Advertisement

Charles River Laboratories Announces Third-Quarter 2026 Results

https://sg.finance.yahoo.com/news/charles-river-laboratories-announces-third-120000344.html
Charles River Laboratories International, Inc. reported strong third-quarter 2026 results, with revenue of $982.7 million and non-GAAP earnings per share up 27.2% year-over-year. The company increased its 2026 guidance for revenue and non-GAAP EPS, citing outperformance in its DSA segment and a lower tax rate. Key initiatives include the "Pathway to Purpose" strategic vision and advancements in modernization and scientific capabilities, such as automated manufacturing and a collaboration with the FDA.

Danaher (DHR), Why Is It Drawing Fresh Attention Today?

https://sg.finance.yahoo.com/news/danaher-dhr-why-drawing-fresh-101407461.html
Danaher (DHR) is gaining attention due to U.S. regulatory clearance of its Access MeMed BV assay, a rapid test for distinguishing bacterial from viral infections. This approval follows strong third-quarter results and positive share price momentum, with the stock showing significant returns over 30 and 90 days. While one narrative suggests Danaher is undervalued with a fair value of $259.90, another perspective based on P/E multiples indicates the shares are trading at a premium compared to sector averages.

What Charles River Doubters Got Wrong Before An 89% Rally

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/what-charles-river-doubters-got-wrong-before-an-89-rally/amp
Charles River Laboratories International experienced an 89.3% return over the past year, surprising some investors who focused on falling net margins. This rally suggests the market is already pricing in strong execution on cost savings and a shift towards higher-margin segments, aligning with bullish narratives about digital modernization and new methodologies. However, analysts note that current prices leave limited room for disappointment if operational risks affect demand, pricing, or margin expansion.

What Charles River Doubters Got Wrong Before An 89% Rally

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/what-charles-river-doubters-got-wrong-before-an-89-rally
Charles River Laboratories International (NYSE:CRL) has seen an 89.3% return for shareholders over the past year, defying earlier doubts based on falling net margins and mixed segment trends. The company's refocus on its "Pathway to Purpose" plan, including divesting certain units and embracing AI-enabled services, supported the bullish narrative despite recent revenue and net loss figures. The current stock price of US$339 reflects strong execution, leaving little room for error if future demand or margin expansion fall short.

Charles River's Q3 Earnings on Deck: What's in Store for the Stock?

https://es.tradingview.com/news/zacks:72fc1c098094b:0-charles-river-s-q3-earnings-on-deck-what-s-in-store-for-the-stock/
Charles River Laboratories International (CRL) is set to release its Q3 2026 earnings, with analysts projecting a 4.8% revenue decline but 22.6% year-over-year EPS growth. The Research Models and Services (RMS) segment is expected to remain under pressure due to lower demand and recent divestitures, while Discovery and Safety Assessment (DSA) may see improved demand in biopharmaceuticals. Manufacturing Solutions is anticipated to benefit from strength in Microbial Solutions and recent technological advancements, despite some divestitures.
Advertisement

Charles River's Q3 Earnings on Deck: What's in Store for the Stock?

https://www.tradingview.com/news/zacks:72fc1c098094b:0-charles-river-s-q3-earnings-on-deck-what-s-in-store-for-the-stock/
Charles River Laboratories International (CRL) is set to announce its third-quarter 2026 earnings on November 4, with analysts projecting a 4.8% revenue decline but 22.6% EPS growth. The Research Models and Services segment is expected to remain under pressure, while the Discovery and Safety Assessment segment may show improvement in biopharmaceutical demand. The Manufacturing Solutions segment is likely to benefit from strong Microbial Solutions and recent technological advancements, though divestitures in various segments are anticipated to impact overall revenue.

Charles River Laboratories International (CRL) Gains Fresh Attention After Research Partnerships Raise Valuation Questions

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/charles-river-laboratories-international-crl-gains-fresh-att
Charles River Laboratories International (CRL) has drawn investor interest due to recent research partnerships with Ipsen, Labcorp, and the U.S. FDA, following significant share price gains. Despite its strong performance, the company's valuation is debated, with Simply Wall St's analysis suggesting it might be 14% overvalued with a fair value of $315.53 against a current price of $359.41. The company aims to shift towards higher-value services like bioanalysis and manufacturing, leveraging AI and internal primate sourcing, to support its long-term profit story.

How AI Testing Partnerships Will Impact Charles River Stock

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/how-ai-testing-partnerships-will-impact-charles-river-stock/amp
Charles River Laboratories International is leveraging AI through partnerships, including one with Ipsen for its Virtual Control Group database in toxicology and another with Labcorp and the FDA to assess medicine abuse potential. These initiatives aim to shift the company's focus towards higher-value preclinical services and improve drug candidate progression efficiency, which could positively impact its financial narrative by moving towards profitability despite existing challenges like high debt and potential shifts to non-animal testing. The financial impact, however, hinges on broader adoption and regulatory acceptance of these new methodologies.

IQVIA Holdings Inc. (IQV) stock price, news, quote and history

https://au.finance.yahoo.com/quote/IQV/
IQVIA Holdings Inc. (IQV) is currently trading at $262.69, up 1.64%, with a market capitalization of $43.291 billion. The company, a provider of clinical research and healthcare intelligence services, has shown a year-to-date return of 16.52%. Analysts have an average 1-year target price of $311.89 for IQV, with recent ratings maintaining a "Buy" recommendation.

Charles River Laboratories International, Inc. (CRL) Seasonal returns chart

https://uk.finance.yahoo.com/quote/CRL/seasonality/
This article from Yahoo Finance presents a seasonal returns chart for Charles River Laboratories International, Inc. (CRL). It displays the average monthly price return for CRL over various periods, including 3, 5, 10, and 20 years, as well as an "All" data option from 2016-2026. The current stock price and after-hours trading information are also provided.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement